Telix Pharmaceuticals Ltd (TLX) Form 6-K — Sep 21, 2026
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE, acquiring 100% of the private German radioisotope leader for US$1.65 billion upfront on a cash-free/debt-free basis plus up to US$700 million in contingent milestones. ITM holders will receive approximately US$1.25 billion in 105.8 million Telix shares priced at US$11.841, leaving them with about 23.7% of the combined company after closing.
Key figures
- Revenue
- Pro forma Telix + ITM 2026 revenue and income exceeding US$1.3B (management estimate, unaudited)
- Cash Position
- 325000000
- Deal Value Usd
- 1650000000
- Offering Price
- 11.841
- Shares Offered
- 105800000
- End date
- December 31, 2026 (extendable three months for regulatory delays)
- Escrow period
- up to 15 months
- Expected close
- by end of FY 2026
- Fda milestones
- US$100M G1-G2 GEP-NETs approval by Dec 31 2027; US$100M G2-G3 by Dec 31 2030; US$50M lung NETs by Dec 31 2031
- Sales milestone
- 3.0x ITM-11 FY2030 net sales in excess of US$150M, capped at US$450M
- Assumed net debt
- US$302M
- Itm 2025 revenue
- US$273M (audited)
- Targeted synergies
- US$50M in first two years
- Itm h1 2026 revenue
- US$156M (unaudited)
- Contingent consideration
- up to US$700M (US$250M regulatory milestones + up to US$450M FY2030 sales milestone)
- Itm revenue cagr 2021 2025
- 40%
- Shareholder vote failure fee
- US$5M
- Combined pro forma market cap
- US$5.3B
- Itm holders ownership post close
- 23.7%
- Management rollover and expenses
- US$96M
- Telix holders ownership post close
- 76.3%
- Itm fy2026 annualized manufacturing ebitda
- US$106M (unaudited)
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.